haloacid dehalogenase like hydrolase domain containing 3Genealiases: 2810435D12Rik · C9orf158
Q-omics provides the consensus-scored HDHD3 profile across patient tissues and cancer cell-line models. HDHD3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HDHD3 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, HDHD3 protein abundance shows 34,406 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, and GBM as cancer lineages where HDHD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDHD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDHD3 survival associations across molecular data types. HDHD3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDHD3 RNA expression–survival associations across cancer types. High HDHD3 expression shows unfavorable associations in LGG, UCS, ESCA and PRAD, but favorable associations in KIRP and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify KIRP as the clearest survival context for HDHD3 RNA expression.
This table summarizes HDHD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HDHD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDHD3 shows lower tumor expression in KIRP and KICH and higher tumor expression in LUSC, LUAD, LIHC and BLCA. The KIRP box plot shows higher HDHD3 RNA expression in normal versus tumor tissue (log2 FC = −1.040, t-test p < 0.001).
This table shows molecular features associated with HDHD3 in patient tissues and cancer cell lines. In patient samples, HDHD3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HDHD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
